{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:51:07Z","timestamp":1770270667543,"version":"3.49.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 76-year-old man with metastatic adenocarcinoma of the prostate presented with increasing dyspnea. After being treated initially with drainage and afterwards with pleurodesis, he was referred for <jats:sup>68<\/jats:sup>Ga\u2013prostate-specific membrane antigen 11 PET\/CT imaging for restaging purposes. PET\/CT demonstrated extensive <jats:sup>68<\/jats:sup>Ga\u2013prostate-specific membrane antigen 11 uptake in the right pleura. Histopathology confirmed the rare case of malignant pleural effusion from metastatic prostate cancer.<\/jats:p>","DOI":"10.1097\/rlu.0000000000002748","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T15:55:12Z","timestamp":1562601312000},"page":"838-839","source":"Crossref","is-referenced-by-count":3,"title":["68Ga\u2013Prostate-Specific Membrane Antigen Uptake in a Malignant Pleural Effusion From Metastatic Prostate Cancer After Pleurodesis"],"prefix":"10.1097","volume":"44","author":[{"given":"Christos","family":"Sachpekidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Afshar-Oromieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/1097-0142(19950601)75:11<2706::AID-CNCR2820751111>3.0.CO;2-Y","article-title":"Pulmonary metastases from prostate cancer","volume":"75","year":"1995","journal-title":"Cancer"},{"key":"bib2-20230925","first-page":"24","article-title":"Malignant pleural effusion from prostate adenocarcinoma","volume":"13","year":"2014","journal-title":"Respir Med Case Rep"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1097\/RLU.0000000000001349","article-title":"68Ga-PSMA-11 dynamic PET\/CT imaging in primary prostate cancer","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","year":"2016","journal-title":"J Urol"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00259-017-3780-7","article-title":"Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)\u2013targeted PET imaging","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:01:45Z","timestamp":1695621705000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002748","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,8]]}}}